White blood cell count as a powerful prognostic marker and treatment guide in paediatric acute myeloid leukaemia with NUP98 rearrangement
British Journal of Haematology · 2025
DOI: 10.1111/bjh.70096 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Hui Shi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Precision Oncology and Intelligent Theranostics Laboratory, Department of Pediatric Hematology and Oncology, Chongqing Key Laboratory of Pediatric Me…. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Nuclear Pore Complex Proteins, Gene Rearrangement. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Science and Technology Research Program of Chongqing Municipal Education Commission, Chongqing medical scientific research project, CQMU Program for Youth Innovation in Future Medicine.
Abstract (Originalsprache)
NUP98 ‐rearranged paediatric acute myeloid leukaemia ( NUP98 ‐r pAML) has an extremely poor prognosis, and the impact of clinical parameters and therapeutic schemes on its outcomes remains unclear. We conducted a retrospective study of the largest pAML cohort (1779 patients) and found that NUP98 ‐r pAML has the worst prognosis among all subtypes. Furthermore, we identified white blood cell (WBC) count as the sole predictor of overall survival (OS) in NUP98 ‐r pAML patients and validated its adverse prognostic impact in both external paediatric and adult cohorts. NUP98 ‐r pAML patients were categorized into low‐risk (WBC count ≤150 × 10 9 /L) and high‐risk (WBC count >150 × 10 9 /L) groups based on WBC levels. Haematopoietic stem cell transplantation (HSCT) significantly improved OS and reduced the cumulative incidence of relapse (CIR) in the high‐risk group but not in the low‐risk group. Bortezomib significantly increased OS in NUP98::NSD1 patients within the low‐risk group, and the combination of bortezomib and HSCT significantly enhanced OS in the entire NUP98 ‐r pAML cohort. CD33 antibody (Gemtuzumab ozogamicin, GO) is not recommended for the entire NUP98 ‐r pAML patients. In summary, WBC count is a pivotal marker for risk stratification and treatment decision‐making in NUP98 ‐r pAML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Oncology and Intelligent Theranostics Laboratory, Department of Pediatric Hematology and Oncology, Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Ministry of Education Key Laborato…
- Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
- Department of Basic Medicine, School of Medicine, Foshan University, Foshan, Guangdong Province, China.
- Faculty of Medicine, Macau University of Science and Technology, Macau, SAR, China.
- School of Medicine, University of Dundee, Dundee, UK.
- Macau Institute for Artificial Intelligence in Medicine, Macau University of Science and Technology, Macau, SAR, China.
Förderung
- Science and Technology Research Program of Chongqing Municipal Education Commission
- Chongqing medical scientific research project
- CQMU Program for Youth Innovation in Future Medicine
Zitieren
APA
Shi, H., Shu, W., Tao, Y., Jia, X., Shen, Y., Yang, H., Xun, Y., Baptista-Hon, D. T., & You, H. (2025). White blood cell count as a powerful prognostic marker and treatment guide in paediatric acute myeloid leukaemia with NUP98 rearrangement. British Journal of Haematology. https://doi.org/10.1111/bjh.70096
Vancouver
Shi H, Shu W, Tao Y, Jia X, Shen Y, Yang H, et al. White blood cell count as a powerful prognostic marker and treatment guide in paediatric acute myeloid leukaemia with NUP98 rearrangement. British Journal of Haematology. 2025. doi:10.1111/bjh.70096
BibTeX
@article{Shi2025,
author = {Shi, Hui and Shu, Wenjing and Tao, Yu and Jia, Xueming and Shen, Yali and Yang, Hua and Xun, Yang and Baptista-Hon, Daniel Tomas and You, Hua},
title = {White blood cell count as a powerful prognostic marker and treatment guide in paediatric acute myeloid leukaemia with NUP98 rearrangement},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.70096}
}
EUVIMED